Alexion Pharmaceuticals Inc., of Cheshire, Conn., reported first quarter earnings, tallying net product sales of Soliris (eculizumab) of $600.3 million, compared to $566.6 million for the same period in 2014, which included reimbursement of $87.8 million from shipments in prior years related to an agreement with the French government.